Taking advantage of their cell surface nature, many cancer‐associated glycobiomarkers (CA72‐4; CA19‐9; CA125 which detects MUC16, CEA) have been exploited for noninvasive cancer detection, follow‐up and therapy development (Bottoni and Scatena, 2015; Santos et al., 2014; Silva, 2015). This evidence concerns the gene MUC16 and cancer.